← back to search

Ali Fatemi

Kennedy Krieger Institute · US
Area of research
Molecular Biology · Clinical Biochemistry
Research interest
Research interests include Peroxisome Proliferator-Activated Receptors, Metabolism and Genetic Disorders, RNA regulation and disease, and Neonatal and fetal brain pathology.
h-index
49
citations
8,223
works
169
NIH funding
primary concept
Medicine
email

Recent publications

AAV9-DARS2 Gene Therapy Rescues Phenotype in Leukoencephalopathy with Brainstem and Spinal Cord Involvement and Lactate Elevation Patient Cells and Neuronal Dars2 Deficient Mice.
2026cited by 0position: contributordoi
Risk of Seizures and Epilepsy in the Leukodystrophies.
2026cited by 0position: contributordoi
Evidence of Iron Accumulation in Cerebral Adrenoleukodystrophy: A Potential Novel Disease Mechanism.
2026cited by 0position: contributordoi
Use of Brain MRI in Cerebral Adrenoleukodystrophy: International Recommendations for Screening, Monitoring, and Research.
2026cited by 0position: contributordoi
Consensus-Based Expert Recommendations for Diagnosis and Clinical Management of Vanishing White Matter.
2025cited by 1position: contributordoi
Clinically Important Endpoints in Individuals With Leukodystrophy: A Multisite Study
Annals of the Child Neurology Society 2025cited by 0position: middledoi
Clinically Important Endpoints in Individuals With Leukodystrophy: A Multisite Study.
2025cited by 0position: contributordoi
Reporting ABCD1 variants as actionable secondary findings on exome and genome sequencing.
2025cited by 0position: contributordoi
Consensus guidelines for the monitoring and management of metachromatic leukodystrophy in the United States
Cytotherapy 2024cited by 24position: middledoi
Longitudinal natural history studies based on real-world data in rare diseases: Opportunity and a novel approach
Molecular Genetics and Metabolism 2024cited by 21position: middledoi
Consensus guidelines for the monitoring and management of metachromatic leukodystrophy in the United States.
2024cited by 19position: contributordoi
Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy
Brain 2024cited by 18position: middledoi
Longitudinal natural history studies based on real-world data in rare diseases: Opportunity and a novel approach.
2024cited by 14position: contributordoi
Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy.
2024cited by 12position: contributordoi
International validation of meaningfulness of postural sway and gait to assess myeloneuropathy in adults with adrenoleukodystrophy.
2024cited by 7position: contributordoi
De novo variants in DENND5B cause a neurodevelopmental disorder.
2024cited by 7position: contributordoi
Developmental delay can precede neurologic regression in early onset metachromatic leukodystrophy.
2024cited by 5position: contributordoi
Practical Approach to Longitudinal Neurologic Care of Adults With X-Linked Adrenoleukodystrophy and Adrenomyeloneuropathy.
2024cited by 5position: contributordoi
Letter to the Editor: The Application of Interleukin-1 Antagonists in Patients With Megalencephalic Leukoencephalopathy With Subcortical Cysts: Caution Warranted
Pediatric Neurology 2024cited by 0position: contributordoi
Sphingolipid desaturase DEGS1 is essential for mitochondria-associated membrane integrity.
2023cited by 33position: contributordoi
Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2-3 trial.
2023cited by 31position: contributordoi
Clinical and functional consequences of GRIA variants in patients with neurological diseases.
2023cited by 13position: contributordoi
A Phase 1 Study of Oral Vitamin D<sub>3</sub> in Boys and Young Men With X-Linked Adrenoleukodystrophy.
2023cited by 7position: contributordoi
Targeted Brain Delivery of Dendrimer-4-Phenylbutyrate Ameliorates Neurological Deficits in a Long-Term ABCD1-Deficient Mouse Model of X-Linked Adrenoleukodystrophy.
2023cited by 5position: contributordoi
Core protocol development for phase 2/3 clinical trials in the leukodystrophy vanishing white matter: a consensus statement by the VWM consortium and patient advocates.
2023cited by 4position: contributordoi
Core protocol development for phase 2/3 clinical trials in the leukodystrophy Vanishing White Matter
2023cited by 0position: contributordoi
Integrating de novo and inherited variants in 42,607 autism cases identifies mutations in new moderate-risk genes
Nature Genetics 2022cited by 450position: middledoi
International Recommendations for the Diagnosis and Management of Patients With Adrenoleukodystrophy
Neurology 2022cited by 136position: middledoi
International Recommendations for the Diagnosis and Management of Patients With Adrenoleukodystrophy: A Consensus-Based Approach.
2022cited by 77position: contributordoi
Antisense Oligonucleotide Therapy for the Nervous System: From Bench to Bedside with Emphasis on Pediatric Neurology.
2022cited by 47position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 7 papers (2020–2026)Keith P. Van Haren · Stanford University5 papers (2022–2026) · 5 papers (2022–2026)Marc Engelen · Children's Hospital of Philadelphia5 papers (2022–2026)Keith Van Haren · Stanford University4 papers (2015–2024)Cas Simons · Royal Children's Hospital4 papers (2019–2020)Florian Eichler · Harvard University3 papers (2015–2024)Lawrence Steinman · Stanford University3 papers (2022–2023)Julian A. Martinez-Agosto · Massachusetts General Hospital3 papers (2019–2024)Joshua Bonkowsky · Precision for Medicine (United States)3 papers (2022–2026)Marjo S. van der Knaap · Eindhoven University of Technology3 papers (2022–2025)Ettore Salsano · Fondazione IRCCS Istituto Neurologico Carlo Besta3 papers (2022–2026)Stanley F Nelson · Institute of Human Genetics3 papers (2019–2024)Jennifer L. Orthmann-Murphy · University of Pennsylvania3 papers (2024–2026)Adeline Vanderver · Children's Hospital of Philadelphia3 papers (2019–2025)Fanny Mochel · Centre National de la Recherche Scientifique3 papers (2022–2026)Adeline Vanderver · University of Colorado Denver3 papers (2020–2024)Gerald V. Raymond · Johns Hopkins Hospital3 papers (2015–2022)Devin Oglesbee · Mayo Clinic2 papers (2019–2019) · 2 papers (2020–2024)